LAUSR

Negative allosteric modulators of N‐methyl‐ d‐aspartate receptors containing the GluN2B subunit represent promising drug candidates for the treatment of various neurological disorders including stroke, epilepsy, and Parkinson's disease. To increase the bioavailability and GluN2B affinity, the phenol of the potent benzazepine‐based inhibitor, WMS‐1410 (3), was replaced bioisosterically by a benzoxazolone moiety and the phenylbutyl side chain was conformationally restricted in a phenylcyclohexyl substituent. A four‐step, one‐pot procedure transformed the oxazolo‐benzazepine 7 into the phenylcyclohexyl derivative 11. The same protocol was applied to the methylated analog 12, which unexpectedly led to ring‐contracted oxazolo‐isoquinolines 18. This rearrangement was explained by the additional methyl moiety in the 8‐position inhibiting the formation of the planar intermediate iminium ion with phenylcyclohexanone. The allyl protective group of 11 and 18 was removed with RhCl3 and HCl to obtain the tricyclic compounds 5 and 19 without substituent at the oxazolone ring. The structures of the rearranged products 18 and 19 were elucidated by X‐ray crystal structure analysis. The oxazolo‐isoquinoline trans‐18 with allyl moiety (Ki = 89 nM) and the oxazolo‐benzazepine 5 without substituent at the oxazolone ring (Ki = 114 nM) showed GluN2B affinity in the same range as the lead compound 3. In two‐electrode voltage clamp measurements, 5 displayed only weak inhibitory activity.